US 12,227,779 B2
Modified DDAH polypeptides and their use to extracorporeally treat a patient's blood to reduce levels of ADMA
Jaipal Singh, Carmel, IN (US)
Assigned to THE TRUSTEES OF INDIANA UNIVERSITY, Bloomington, IN (US)
Filed by THE TRUSTEES OF INDIANA UNIVERSITY, Bloomington, IN (US)
Filed on Mar. 9, 2022, as Appl. No. 17/690,657.
Application 17/690,657 is a continuation of application No. 16/777,413, filed on Jan. 30, 2020.
Application 16/777,413 is a continuation in part of application No. PCT/US2018/044627, filed on Jul. 31, 2018.
Claims priority of provisional application 62/539,261, filed on Jul. 31, 2017.
Prior Publication US 2022/0204961 A1, Jun. 30, 2022
Int. Cl. C12N 9/78 (2006.01); A61K 38/50 (2006.01)
CPC C12N 9/78 (2013.01) [A61K 38/50 (2013.01); C12Y 305/03018 (2013.01)] 14 Claims
 
1. A system comprising a DDAH polypeptide for extracorporeally treating a patient's blood and reducing ADMA levels in said blood, said system comprising
a DDAH polypeptide and
a solid support, wherein said DDAH polypeptide is covalently linked to said solid support; and
a device configured to receive a patient's blood and return the blood to the patient's circulation after contact with said solid support, wherein said device comprises said solid support in a configuration that places said solid support in fluid communication with blood that passes through the device, wherein said blood has reduced ADMA levels after contacting the solid support relative to the ADMA levels in the blood prior to contact with the solid support.